Bausch Health Companies Inc. (NYSE:BHC) Given Average Recommendation of “Hold” by Analysts

Bausch Health Companies Inc. (NYSE:BHC) has earned an average rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $7.75.

Several brokerages recently weighed in on BHC. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Royal Bank of Canada boosted their target price on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a report on Friday, November 1st. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th.

Bausch Health Companies Trading Up 0.5 %

NYSE:BHC opened at $7.65 on Friday. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46. The company has a 50-day moving average price of $8.25 and a 200-day moving average price of $7.32. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -15.94 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same period last year, the business posted $1.03 earnings per share. Bausch Health Companies’s quarterly revenue was up 12.2% compared to the same quarter last year. Equities analysts forecast that Bausch Health Companies will post 3.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

Hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC purchased a new position in Bausch Health Companies in the second quarter worth about $35,000. MQS Management LLC bought a new stake in shares of Bausch Health Companies during the second quarter valued at approximately $71,000. Certuity LLC purchased a new position in Bausch Health Companies in the 2nd quarter worth approximately $75,000. Bfsg LLC lifted its position in Bausch Health Companies by 46.7% in the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after acquiring an additional 3,643 shares in the last quarter. Finally, Kendall Capital Management purchased a new stake in Bausch Health Companies during the 2nd quarter valued at $87,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.